董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Steven Boyd | 男 | Director | 40 | 未披露 | 未持股 | 2021-04-30 |
| June Almenoff | 女 | Director | 64 | 未披露 | 未持股 | 2021-04-30 |
| Declan Doogan | 男 | Director | 69 | 未披露 | 未持股 | 2021-04-30 |
| Keith Maher | 男 | Director | 53 | 未披露 | 未持股 | 2021-04-30 |
| Michael Davidson | 男 | Director | 64 | 未披露 | 未持股 | 2021-04-30 |
| Stuart Rich | 男 | Chief Medical Officer and Director | 71 | 未披露 | 未持股 | 2021-04-30 |
| Anthony A. DiTonno | 男 | Chief Executive Officer and Director | 72 | 5.50万美元 | 未持股 | 2021-04-30 |
| Gerald T. Proehl | 男 | Chair | 62 | 6.19万美元 | 未持股 | 2021-04-30 |
| James Mitchum | 男 | Director | 68 | 4.87万美元 | 未持股 | 2021-04-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Stuart Rich | 男 | Chief Medical Officer and Director | 71 | 未披露 | 未持股 | 2021-04-30 |
| Anthony A. DiTonno | 男 | Chief Executive Officer and Director | 72 | 5.50万美元 | 未持股 | 2021-04-30 |
| Michael B. Jebsen | 男 | President and Chief Financial Officer | 49 | 42.50万美元 | 未持股 | 2021-04-30 |
董事简历
中英对照 | 中文 | 英文- Steven Boyd
-
Steven Boyd，自本公司2014年2月的私募发行之时起，就担任Reverse Mortgage Investment Trust Inc的董事。2010年5月起，他担任BlueMountain Capital Management, LLC的投资组合经理，领导住宅按揭团队，管理着多项投资业务，涉及非机构抵押贷款支持证券、机构信用风险交易、与抵押贷款公司的战略伙伴关系。2005年3月至2009年11月，他是Citadel Investment Group的投资组合经理，曾是全球证券化产品团队的一员；任职期间，他在整个2008年信贷风险时期，管理着长/短期、不良抵押产品的策略，并实施了一些著名的交易，其中包括金融服务公司E Trade Financial Corporation、按揭发起及特别服务商ResMAE Mortgage Corp的收购。
Steven Boyd has served as a director since July 2020. Mr. Boyd has served since 2012 as the chief investment officer of Armistice Capital, LLC "Armistice", a long-short equity hedge fund focused on the health care and consumer sectors. From 2005 to 2012 Mr. Boyd was a research analyst at Senator Investment Group, York Capital and SAB Capital Management, where he focused on health care. Mr. Boyd began his career as an analyst at McKinsey & Company. Mr. Boyd currently serves as a member of the boards of directors of Aytu BioScience, Inc., Cerecor Inc. and EyeGate Pharmaceuticals, Inc. Mr. Boyd received a B.S. in economics and a B.A. in political science from The Wharton School of the University of Pennsylvania. - Steven Boyd，自本公司2014年2月的私募发行之时起，就担任Reverse Mortgage Investment Trust Inc的董事。2010年5月起，他担任BlueMountain Capital Management, LLC的投资组合经理，领导住宅按揭团队，管理着多项投资业务，涉及非机构抵押贷款支持证券、机构信用风险交易、与抵押贷款公司的战略伙伴关系。2005年3月至2009年11月，他是Citadel Investment Group的投资组合经理，曾是全球证券化产品团队的一员；任职期间，他在整个2008年信贷风险时期，管理着长/短期、不良抵押产品的策略，并实施了一些著名的交易，其中包括金融服务公司E Trade Financial Corporation、按揭发起及特别服务商ResMAE Mortgage Corp的收购。
- Steven Boyd has served as a director since July 2020. Mr. Boyd has served since 2012 as the chief investment officer of Armistice Capital, LLC "Armistice", a long-short equity hedge fund focused on the health care and consumer sectors. From 2005 to 2012 Mr. Boyd was a research analyst at Senator Investment Group, York Capital and SAB Capital Management, where he focused on health care. Mr. Boyd began his career as an analyst at McKinsey & Company. Mr. Boyd currently serves as a member of the boards of directors of Aytu BioScience, Inc., Cerecor Inc. and EyeGate Pharmaceuticals, Inc. Mr. Boyd received a B.S. in economics and a B.A. in political science from The Wharton School of the University of Pennsylvania.
- June Almenoff
-
June Almenoff自2019年5月15日起担任我们的首席科学官。Almenoff博士在制药行业拥有20多年的经验，曾担任多个高级执行职位，包括被Actavis plc收购的Furiex Pharmaceuticals的总裁兼首席医疗官，Actavis plc现为Allergan plc，其主导产品Viberzi®；，于2015年被FDA批准用于治疗肠易激综合征合并腹泻（IBS-D）。在加入Furiex之前，Almenoff博士曾在GlaxoSmithKline plc工作，在那里她担任多个职责递增的职位。她最近担任众多生物制药公司的董事会成员和顾问。她目前是Harrington Discovery Institute和Brainstorm Cell Therapeutics（NASDAQ:BCLI）的Harrington投资顾问委员会的董事会成员。Almenoff博士拥有史密斯学院（Smith College）的B.A.（优等生），并毕业于西奈山医学院（Mt.Sinai School of Medicine）的医学博士-博士项目。她在斯坦福大学医学中心（Stanford University Medical Center）完成内科住院医师和传染病奖学金培训，并任职于杜克大学医学院（Duke University School of Medicine）的教员，在那里她目前担任兼职。
June Almenoff, has served as a director since February 2021. Dr. Almenoff is an accomplished biopharma executive with over 20 years of senior leadership experience. She served as President and Chief Medical Officer of Furiex Pharmaceuticals “Furiex”, which was acquired by Actavis plc now AbbVie for $1.2B. Furiex developed eluxadoline Viberzi®, which is approved in both the United States and Europe. Prior to joining Furiex, Dr. Almenoff was at GlaxoSmithKline (GSK) for 12 years, where she held various positions of increasing responsibility. She was a Vice President in the Clinical Safety Organization, chaired a PhRMA-FDA working group, and worked in the area of scientific licensing. Dr. Almenoff also led the development of pioneering systems for minimizing risk in drug development, which have been widely adopted by industry and regulators. Dr. Almenoff led or contributed to numerous regulatory submissions and product approvals. She is currently Chief Medical Officer of RedHill Biopharma (Nasdaq: RDHL). She also serves on the investment advisory board of the Harrington Discovery Institute and the boards of Brainstorm Cell Therapeutics (Nasdaq: BCLI) and inSoma Bio. Dr. Almenoff has strong expertise in translational medicine, clinical development, commercial strategy, and business development, and has previously advised biotech boards and management in these areas. Dr. Almenoff received her B.A. cum laude from Smith College and graduated with AOA honors from the M.D.-Ph.D. program at the Icahn (Mt. Sinai) School of Medicine. She completed post-graduate medical training at Stanford University Medical Center and served on the faculty of Duke University School of Medicine. She is an adjunct professor at Duke, a Fellow of the American College of Physicians (FACP) and has authored close to 60 publications. - June Almenoff自2019年5月15日起担任我们的首席科学官。Almenoff博士在制药行业拥有20多年的经验，曾担任多个高级执行职位，包括被Actavis plc收购的Furiex Pharmaceuticals的总裁兼首席医疗官，Actavis plc现为Allergan plc，其主导产品Viberzi®；，于2015年被FDA批准用于治疗肠易激综合征合并腹泻（IBS-D）。在加入Furiex之前，Almenoff博士曾在GlaxoSmithKline plc工作，在那里她担任多个职责递增的职位。她最近担任众多生物制药公司的董事会成员和顾问。她目前是Harrington Discovery Institute和Brainstorm Cell Therapeutics（NASDAQ:BCLI）的Harrington投资顾问委员会的董事会成员。Almenoff博士拥有史密斯学院（Smith College）的B.A.（优等生），并毕业于西奈山医学院（Mt.Sinai School of Medicine）的医学博士-博士项目。她在斯坦福大学医学中心（Stanford University Medical Center）完成内科住院医师和传染病奖学金培训，并任职于杜克大学医学院（Duke University School of Medicine）的教员，在那里她目前担任兼职。
- June Almenoff, has served as a director since February 2021. Dr. Almenoff is an accomplished biopharma executive with over 20 years of senior leadership experience. She served as President and Chief Medical Officer of Furiex Pharmaceuticals “Furiex”, which was acquired by Actavis plc now AbbVie for $1.2B. Furiex developed eluxadoline Viberzi®, which is approved in both the United States and Europe. Prior to joining Furiex, Dr. Almenoff was at GlaxoSmithKline (GSK) for 12 years, where she held various positions of increasing responsibility. She was a Vice President in the Clinical Safety Organization, chaired a PhRMA-FDA working group, and worked in the area of scientific licensing. Dr. Almenoff also led the development of pioneering systems for minimizing risk in drug development, which have been widely adopted by industry and regulators. Dr. Almenoff led or contributed to numerous regulatory submissions and product approvals. She is currently Chief Medical Officer of RedHill Biopharma (Nasdaq: RDHL). She also serves on the investment advisory board of the Harrington Discovery Institute and the boards of Brainstorm Cell Therapeutics (Nasdaq: BCLI) and inSoma Bio. Dr. Almenoff has strong expertise in translational medicine, clinical development, commercial strategy, and business development, and has previously advised biotech boards and management in these areas. Dr. Almenoff received her B.A. cum laude from Smith College and graduated with AOA honors from the M.D.-Ph.D. program at the Icahn (Mt. Sinai) School of Medicine. She completed post-graduate medical training at Stanford University Medical Center and served on the faculty of Duke University School of Medicine. She is an adjunct professor at Duke, a Fellow of the American College of Physicians (FACP) and has authored close to 60 publications.
- Declan Doogan
-
Declan Doogan自2013年9月公司成立以来一直担任公司董事。Doogan博士曾担任Portage Biotech，Inc.的首席执行官兼董事。PTGEF:OTCBB自2013年6月起担任Portage Pharmaceuticals Limited董事，自2007年6月起担任Sosei Group Corporation董事。Doogan博士在主要制药和生物技术领域拥有超过30年的行业经验。他曾担任Pfizer公司的高级副总裁兼全球开发主管。他曾担任Pfizer公司的美国、英国和日本的多种执行职务。2007年离开Pfizer以来，他一直担任小型制药公司的执行职务。Doogan博士曾是Amarin（AMRN:NASDAQ）的首席医疗官和代理首席执行官。他也一直担任Prometheus Laboratories公司（圣地亚哥的分子诊断公司）的首席医疗官。Doogan博士拥有多个董事会任命，主要在制药公司，也曾在哈佛大学公共卫生学院、格拉斯哥大学医学院和北里大学（东京）担任教授。Doogan博士于1975年在格拉斯哥大学（Glasgow University）获得医学学位。他是the Royal College of Physicians和the Faculty of Pharmaceutical Medicine的研究员，持有英国肯特大学（the University of Kent）的科学博士学位。
Declan Doogan has served as a director since February 2021. Dr. Doogan has over 30 years of industry experience in both major pharma and biotech. He was the Senior Vice President and Head of Worldwide Development at Pfizer, where many multibillion-dollar programs were delivered e.g., Viagra, Lipitor and Zoloft. He has held a number of executive positions in Pfizer in the U.S., the U.K. and Japan. Since leaving Pfizer in 2007 he has been engaged in executive roles in small pharma. Declan was CMO and acting CEO of Amarin AMRN: Nasdaq, transforming it from a failing neuroscience company to a vibrant cardiovascular company with a market capitalization of over one billion dollars before his departure. He is Chairman and co-founder of Biohaven BHVN:NYSE and an investor in emerging biotechnology and technology companies. He holds a number of Board appointments, principally in pharma companies, and is also a visiting professor at Glasgow University Medical School. Dr. Doogan received his medical degree from Glasgow University in 1975. He is a Fellow of the Royal College of Physicians and the Faculty Pharmaceutical Medicine and holds a Doctorate of Science at the University of Kent in the U.K. - Declan Doogan自2013年9月公司成立以来一直担任公司董事。Doogan博士曾担任Portage Biotech，Inc.的首席执行官兼董事。PTGEF:OTCBB自2013年6月起担任Portage Pharmaceuticals Limited董事，自2007年6月起担任Sosei Group Corporation董事。Doogan博士在主要制药和生物技术领域拥有超过30年的行业经验。他曾担任Pfizer公司的高级副总裁兼全球开发主管。他曾担任Pfizer公司的美国、英国和日本的多种执行职务。2007年离开Pfizer以来，他一直担任小型制药公司的执行职务。Doogan博士曾是Amarin（AMRN:NASDAQ）的首席医疗官和代理首席执行官。他也一直担任Prometheus Laboratories公司（圣地亚哥的分子诊断公司）的首席医疗官。Doogan博士拥有多个董事会任命，主要在制药公司，也曾在哈佛大学公共卫生学院、格拉斯哥大学医学院和北里大学（东京）担任教授。Doogan博士于1975年在格拉斯哥大学（Glasgow University）获得医学学位。他是the Royal College of Physicians和the Faculty of Pharmaceutical Medicine的研究员，持有英国肯特大学（the University of Kent）的科学博士学位。
- Declan Doogan has served as a director since February 2021. Dr. Doogan has over 30 years of industry experience in both major pharma and biotech. He was the Senior Vice President and Head of Worldwide Development at Pfizer, where many multibillion-dollar programs were delivered e.g., Viagra, Lipitor and Zoloft. He has held a number of executive positions in Pfizer in the U.S., the U.K. and Japan. Since leaving Pfizer in 2007 he has been engaged in executive roles in small pharma. Declan was CMO and acting CEO of Amarin AMRN: Nasdaq, transforming it from a failing neuroscience company to a vibrant cardiovascular company with a market capitalization of over one billion dollars before his departure. He is Chairman and co-founder of Biohaven BHVN:NYSE and an investor in emerging biotechnology and technology companies. He holds a number of Board appointments, principally in pharma companies, and is also a visiting professor at Glasgow University Medical School. Dr. Doogan received his medical degree from Glasgow University in 1975. He is a Fellow of the Royal College of Physicians and the Faculty Pharmaceutical Medicine and holds a Doctorate of Science at the University of Kent in the U.K.
- Keith Maher
-
Keith Maher自2019年以来一直担任Armistice Capital，LLC的董事总经理。从2007年到2018年，Maher博士在施罗德投资管理公司，欧米茄顾问公司和Gracie Capital担任高级职务。Maher博士是从Valesco梦百合Partners公司加入Gracie公司的，该公司是他与Paramount Bio Capital公司合作创立的一家全球梦百合基金。在创立Valesco之前，Maher博士是Weiss，Peck&Greer WPG Investments的常务董事。他从雷曼兄弟（Lehman Brothers）加入WPG，在那里他担任股票研究分析师，涵盖医疗设备和技术公司。Maher博士目前在EyegatePharmaceuticals，Inc.和Vaxart，Inc.的董事会任职。Maher博士在波士顿大学（Boston University）获得生物学学士学位，在西北大学（Northwestern University）凯洛格管理研究生院（Kellogg Graduate School of Management）获得工商管理硕士学位，在奥尔巴尼医学院（Albany Medical College）获得医学博士学位。Maher博士在医学部西奈山医疗中心（Mount Sinai Medical Center）完成了他的临床培训。
Keith Maher has served as a director since July 2020. Dr. Maher has served as a managing director at Armistice since 2019. From 2007 to 2018 Dr. Maher held senior roles at Schroder Investment Management, Omega Advisors and Gracie Capital. Dr. Maher joined Gracie from Valesco Healthcare Partners, a global healthcare fund he founded in partnership with Paramount Bio Capital. Prior to starting Valesco, Dr. Maher was a managing director at Weiss, Peck & Greer Investments “WPG”. He joined WPG from Lehman Brothers, where he worked as an equity research analyst covering medical device and technology companies. Dr. Maher currently serves on the board EyeGate Pharmaceuticals, Inc. Dr. Maher received a B.A. in biology from Boston University, an M.B.A. from Northwestern University's Kellogg Graduate School of Management and an M.D. from Albany Medical College. Dr. Maher completed his clinical training at the Mount Sinai Medical Center in the Department of Medicine. - Keith Maher自2019年以来一直担任Armistice Capital，LLC的董事总经理。从2007年到2018年，Maher博士在施罗德投资管理公司，欧米茄顾问公司和Gracie Capital担任高级职务。Maher博士是从Valesco梦百合Partners公司加入Gracie公司的，该公司是他与Paramount Bio Capital公司合作创立的一家全球梦百合基金。在创立Valesco之前，Maher博士是Weiss，Peck&Greer WPG Investments的常务董事。他从雷曼兄弟（Lehman Brothers）加入WPG，在那里他担任股票研究分析师，涵盖医疗设备和技术公司。Maher博士目前在EyegatePharmaceuticals，Inc.和Vaxart，Inc.的董事会任职。Maher博士在波士顿大学（Boston University）获得生物学学士学位，在西北大学（Northwestern University）凯洛格管理研究生院（Kellogg Graduate School of Management）获得工商管理硕士学位，在奥尔巴尼医学院（Albany Medical College）获得医学博士学位。Maher博士在医学部西奈山医疗中心（Mount Sinai Medical Center）完成了他的临床培训。
- Keith Maher has served as a director since July 2020. Dr. Maher has served as a managing director at Armistice since 2019. From 2007 to 2018 Dr. Maher held senior roles at Schroder Investment Management, Omega Advisors and Gracie Capital. Dr. Maher joined Gracie from Valesco Healthcare Partners, a global healthcare fund he founded in partnership with Paramount Bio Capital. Prior to starting Valesco, Dr. Maher was a managing director at Weiss, Peck & Greer Investments “WPG”. He joined WPG from Lehman Brothers, where he worked as an equity research analyst covering medical device and technology companies. Dr. Maher currently serves on the board EyeGate Pharmaceuticals, Inc. Dr. Maher received a B.A. in biology from Boston University, an M.B.A. from Northwestern University's Kellogg Graduate School of Management and an M.D. from Albany Medical College. Dr. Maher completed his clinical training at the Mount Sinai Medical Center in the Department of Medicine.
- Michael Davidson
-
Michael Davidson自2021年1月起担任董事会成员。戴维森博士是芝加哥大学的医学教授和脂质诊所主任。他还担任New Amsterdam Pharma的首席执行官。戴维森博士是脂类学领域的领先专家。他进行了1000多项临床试验，发表了350多篇医学期刊文章，并撰写了三本有关脂类学的书籍。他的研究背景包括药物和营养临床试验，包括对他汀类药物、新型降脂药物和欧米茄-3脂肪酸的广泛研究。Davidson博士创立了芝加哥临床研究中心，该中心成为美国最大的研究站点，并于1996年被Pharmaceutical产品开发收购。此外，他于2008年创立了Omthera Pharmaceuticals，该公司于2013年被阿斯利康（AstraZeneca）以4.4亿美元收购，最近，他担任Corvidia Therapeutics的创始首席执行官/CSO，该公司于2020年被Novo Nordisk以高达21亿美元的价格收购。Davidson博士获得了内科，心脏病学和临床脂类学的董事会认证。2010年至2011年，他担任美国国家血脂协会主席，被美国糖尿病协会评为过去15年来美国最好的医生之一，并于2010年被评为年度之父。他也是纳斯达克上市的Caladrius Bioscience的董事会成员。
Michael Davidson has served as a director since February 2021. Dr. Davidson was the Founder and former Chief Scientific Officer of Corvidia Therapeutics, which was recently acquired by Novo-Nordisk for $2.1 billion. Dr. Davidson also serves as Clinical Professor and Director of the Lipid Clinic at the University of Chicago Pritzker School of Medicine. He is a leading expert in the field of Lipidology and was named in The Best Doctors in America for the past 10 years. Dr. Davidson was the co-founding Chief Medical Officer of Omthera Pharmaceuticals in 2008 which was later acquired by Astra Zeneca Pharmaceutical in 2013 for $443M. He also founded the Chicago Center for Clinical Research, which became the largest investigator site in the United States and was acquired by Pharmaceutical Product Development in 1996. His research background encompasses both pharmaceutical and nutritional clinical trials including extensive research on statins, novel lipid-lowering drugs, and omega-3 fatty acids. Dr. Davidson is board-certified in internal medicine, cardiology, and clinical lipidology and served as President of the National Lipid Association from 2010 to 2011. He received his BA/MS from Northwestern University and MD from The Ohio State University School of Medicine. - Michael Davidson自2021年1月起担任董事会成员。戴维森博士是芝加哥大学的医学教授和脂质诊所主任。他还担任New Amsterdam Pharma的首席执行官。戴维森博士是脂类学领域的领先专家。他进行了1000多项临床试验，发表了350多篇医学期刊文章，并撰写了三本有关脂类学的书籍。他的研究背景包括药物和营养临床试验，包括对他汀类药物、新型降脂药物和欧米茄-3脂肪酸的广泛研究。Davidson博士创立了芝加哥临床研究中心，该中心成为美国最大的研究站点，并于1996年被Pharmaceutical产品开发收购。此外，他于2008年创立了Omthera Pharmaceuticals，该公司于2013年被阿斯利康（AstraZeneca）以4.4亿美元收购，最近，他担任Corvidia Therapeutics的创始首席执行官/CSO，该公司于2020年被Novo Nordisk以高达21亿美元的价格收购。Davidson博士获得了内科，心脏病学和临床脂类学的董事会认证。2010年至2011年，他担任美国国家血脂协会主席，被美国糖尿病协会评为过去15年来美国最好的医生之一，并于2010年被评为年度之父。他也是纳斯达克上市的Caladrius Bioscience的董事会成员。
- Michael Davidson has served as a director since February 2021. Dr. Davidson was the Founder and former Chief Scientific Officer of Corvidia Therapeutics, which was recently acquired by Novo-Nordisk for $2.1 billion. Dr. Davidson also serves as Clinical Professor and Director of the Lipid Clinic at the University of Chicago Pritzker School of Medicine. He is a leading expert in the field of Lipidology and was named in The Best Doctors in America for the past 10 years. Dr. Davidson was the co-founding Chief Medical Officer of Omthera Pharmaceuticals in 2008 which was later acquired by Astra Zeneca Pharmaceutical in 2013 for $443M. He also founded the Chicago Center for Clinical Research, which became the largest investigator site in the United States and was acquired by Pharmaceutical Product Development in 1996. His research background encompasses both pharmaceutical and nutritional clinical trials including extensive research on statins, novel lipid-lowering drugs, and omega-3 fatty acids. Dr. Davidson is board-certified in internal medicine, cardiology, and clinical lipidology and served as President of the National Lipid Association from 2010 to 2011. He received his BA/MS from Northwestern University and MD from The Ohio State University School of Medicine.
- Stuart Rich
-
Stuart Rich自2021年1月起担任我们的首席医疗官，自2021年2月起担任董事。Rich博士从PHPM加入公司，他是该公司的联合创始人，并于2018年10月至2021年1月担任首席执行官兼董事。在加入PHPM之前，从2003年10月到2004年12月，Rich博士担任United Therapeutics的兼职首席医疗官。里奇博士目前担任西北大学范伯格医学院的医学教授，并担任英国慈善机构布鲁姆心血管研究所和美国慈善机构心血管医学与研究基金会的肺血管疾病计划主任。在西北大学之前，里奇医生是医学教授。从1980年7月到1996年7月，担任芝加哥伊利诺伊大学医学院心脏科科长，从1996年7月到2004年9月，担任拉什大学医学院拉什心脏研究所的医学教授。2004年9月至2015年7月，担任芝加哥大学普里茨克医学院心脏病学部分的医学教授。里奇博士在伊利诺伊大学获得生物学学士学位，在洛约拉大学斯特里奇医学院获得医学博士学位，并在华盛顿圣路易斯大学完成了医学住院医师学位，在芝加哥大学获得了心脏病学奖学金。
Stuart Rich has served as our Chief Medical Officer since January 2021 and a director since February 2021. Dr. Rich joined the Company from PHPM, where he was a co-founder and held the positions of Chief Executive Officer and Director from October 2018 until January 2021. Prior to PHPM, Dr. Rich served as the Chief Medical Officer part-time of United Therapeutics from October 2003 until December 2004. Dr. Rich currently serves as Professor of Medicine at Northwestern University Feinberg School of Medicine and as Director of the Pulmonary Vascular Disease Program at the Bluhm Cardiovascular Institute, a U.K. based charity, and of the Cardiovascular Medical and Research Foundation, a U.S. based charity. Prior to Northwestern University, Dr. Rich was the Professor of Medicine and Chief of the Section of Cardiology at the University of Illinois College of Medicine in Chicago from July 1980 until July 1996 was Professor of Medicine at the Rush Heart Institute of the Rush University School of Medicine from July 1996 until September 2004 and was Professor of Medicine at the Section of Cardiology of the University of Chicago Pritzker School of Medicine from September 2004 until July 2015. Dr. Rich received his B.S. in Biology at the University of Illinois and his M.D. at Loyola University Stritch School of Medicine, and he completed his residency in medicine at the Washington University of St. Louis and his fellowship in cardiology at the University of Chicago. - Stuart Rich自2021年1月起担任我们的首席医疗官，自2021年2月起担任董事。Rich博士从PHPM加入公司，他是该公司的联合创始人，并于2018年10月至2021年1月担任首席执行官兼董事。在加入PHPM之前，从2003年10月到2004年12月，Rich博士担任United Therapeutics的兼职首席医疗官。里奇博士目前担任西北大学范伯格医学院的医学教授，并担任英国慈善机构布鲁姆心血管研究所和美国慈善机构心血管医学与研究基金会的肺血管疾病计划主任。在西北大学之前，里奇医生是医学教授。从1980年7月到1996年7月，担任芝加哥伊利诺伊大学医学院心脏科科长，从1996年7月到2004年9月，担任拉什大学医学院拉什心脏研究所的医学教授。2004年9月至2015年7月，担任芝加哥大学普里茨克医学院心脏病学部分的医学教授。里奇博士在伊利诺伊大学获得生物学学士学位，在洛约拉大学斯特里奇医学院获得医学博士学位，并在华盛顿圣路易斯大学完成了医学住院医师学位，在芝加哥大学获得了心脏病学奖学金。
- Stuart Rich has served as our Chief Medical Officer since January 2021 and a director since February 2021. Dr. Rich joined the Company from PHPM, where he was a co-founder and held the positions of Chief Executive Officer and Director from October 2018 until January 2021. Prior to PHPM, Dr. Rich served as the Chief Medical Officer part-time of United Therapeutics from October 2003 until December 2004. Dr. Rich currently serves as Professor of Medicine at Northwestern University Feinberg School of Medicine and as Director of the Pulmonary Vascular Disease Program at the Bluhm Cardiovascular Institute, a U.K. based charity, and of the Cardiovascular Medical and Research Foundation, a U.S. based charity. Prior to Northwestern University, Dr. Rich was the Professor of Medicine and Chief of the Section of Cardiology at the University of Illinois College of Medicine in Chicago from July 1980 until July 1996 was Professor of Medicine at the Rush Heart Institute of the Rush University School of Medicine from July 1996 until September 2004 and was Professor of Medicine at the Section of Cardiology of the University of Chicago Pritzker School of Medicine from September 2004 until July 2015. Dr. Rich received his B.S. in Biology at the University of Illinois and his M.D. at Loyola University Stritch School of Medicine, and he completed his residency in medicine at the Washington University of St. Louis and his fellowship in cardiology at the University of Chicago.
- Anthony A. DiTonno
-
Anthony A. DiTonno在2003年8月至2011年12月间，担任公司的首席执行官，总裁和董事。在这之前，2003年初担任公司的首席运营官。Mr. DiTonno在Oxygen Biotherapeutics, Inc.（一个公开上市的生物制药公司）担任董事。2000年10月至2002年11月，Mr. DiTonno担任Enteric Medical Technologies, Inc.（一家医疗设备公司）的销售和营销执行副总裁。1997年至2000年，Mr. DiTonno担任LifeSleep Systems, Inc.（一家医疗设备公司）的首席执行官。1989年至1997年，Mr. DiTonno在Oclassen Pharmaceuticals, Inc.（一家制药公司）担任过许多职务，最近的职务是该公司的副总裁和总经理。Mr. DiTonno在St. Joseph's University获得工商管理学士学位，在Drexel University获得工商管理硕士学位。
Anthony A. DiTonno has served as a director since December 2011 and as Tenax Therapeutics, Inc.'s Chief Executive Officer since June 2018. From January 2013 until May 2018 Mr. DiTonno served as Chief Executive Officer of Avantis Medical Systems, Inc., a medical device company that develops and manufactures catheter-based endoscopic devices. From April 2003 until December 2011 Mr. DiTonno was President and Chief Executive Officer of Neurogesx Inc., a biopharmaceutical company based in the San Francisco Bay area "Neurogesx". During his time at Neurogesx, Mr. DiTonno also served on its board of directors. Mr. DiTonno has funded companies through a variety of financial arrangements including private and public financings, partnerships and debt. He has also been successful in gaining regulatory approvals in both the United States and European Union. Previously, he was Executive Vice President of Marketing and Sales at Enteric Medical Technologies Inc., which was acquired by Boston Scientific Company; President and Chief Executive Officer of Lifesleep Systems, Inc.; and Vice President and General Manager of Olcassen Pharmaceuticals, which was sold to Watson Laboratories. Early in his career, he held a variety of positions of increasing responsibility at Rorer Group, Inc. Rhone Poulenc Rorer and Wyeth Laboratories. Mr. DiTonno received an M.B.A. from Drexel University and a B.S. in Business Administration from St. Joseph's University. - Anthony A. DiTonno在2003年8月至2011年12月间，担任公司的首席执行官，总裁和董事。在这之前，2003年初担任公司的首席运营官。Mr. DiTonno在Oxygen Biotherapeutics, Inc.（一个公开上市的生物制药公司）担任董事。2000年10月至2002年11月，Mr. DiTonno担任Enteric Medical Technologies, Inc.（一家医疗设备公司）的销售和营销执行副总裁。1997年至2000年，Mr. DiTonno担任LifeSleep Systems, Inc.（一家医疗设备公司）的首席执行官。1989年至1997年，Mr. DiTonno在Oclassen Pharmaceuticals, Inc.（一家制药公司）担任过许多职务，最近的职务是该公司的副总裁和总经理。Mr. DiTonno在St. Joseph's University获得工商管理学士学位，在Drexel University获得工商管理硕士学位。
- Anthony A. DiTonno has served as a director since December 2011 and as Tenax Therapeutics, Inc.'s Chief Executive Officer since June 2018. From January 2013 until May 2018 Mr. DiTonno served as Chief Executive Officer of Avantis Medical Systems, Inc., a medical device company that develops and manufactures catheter-based endoscopic devices. From April 2003 until December 2011 Mr. DiTonno was President and Chief Executive Officer of Neurogesx Inc., a biopharmaceutical company based in the San Francisco Bay area "Neurogesx". During his time at Neurogesx, Mr. DiTonno also served on its board of directors. Mr. DiTonno has funded companies through a variety of financial arrangements including private and public financings, partnerships and debt. He has also been successful in gaining regulatory approvals in both the United States and European Union. Previously, he was Executive Vice President of Marketing and Sales at Enteric Medical Technologies Inc., which was acquired by Boston Scientific Company; President and Chief Executive Officer of Lifesleep Systems, Inc.; and Vice President and General Manager of Olcassen Pharmaceuticals, which was sold to Watson Laboratories. Early in his career, he held a variety of positions of increasing responsibility at Rorer Group, Inc. Rhone Poulenc Rorer and Wyeth Laboratories. Mr. DiTonno received an M.B.A. from Drexel University and a B.S. in Business Administration from St. Joseph's University.
- Gerald T. Proehl
-
Gerald T. Proehl于2014年12月成为董事、Dermata Therapeutics, Inc.总裁兼首席执行官，并于2021年4月成为Dermata Therapeutics, Inc.董事长。Proehl先生在制药行业拥有30多年的经验。从2002年1月到2014年1月，Proehl先生担任Santarus, Inc.的总裁兼首席执行官，在那里他以26亿美元的价格将Santarus，Inc.出售给了Salix Pharmaceuticals，Inc.。在加入Santarus, Inc.之前，Proehl先生曾在Hoechst Marion Roussel，Inc.工作了14年，担任过各种职务，包括全球营销副总裁。在Hoechst工作期间，他负责多个治疗领域的产品营销，包括心脏病、过敏/呼吸、免疫学和神经学。Proehl先生拥有纽约州立大学科特兰分校的教育学士学位、维克森林大学的运动生理学硕士学位和罗克赫斯特大学的工商管理硕士学位。Proehl先生目前在一家上市公司Tenax Therapeutics, Inc.（纽约证券交易所代码：TENX）担任Shlomo Kramer。由于Proehl先生在其他公司的领导经验以及他创立和经营专业制药公司的历史，他被选为高级管理人员和董事。
Gerald T. Proehl,became a director and Dermata Therapeutics, Inc. President and Chief Executive Officer in December 2014 and became Dermata Therapeutics, Inc. Chairman in April 2021. From January 2002 until January 2014, Mr. Proehl was President and CEO of Santarus, Inc., where he led the sale of Santarus, Inc. to Salix Pharmaceuticals, Inc. for $2.6 billion. Prior to Santarus, Inc., Mr. Proehl worked for Hoechst Marion Roussel, Inc. for 14 years, where he served in various capacities, including VP of Global Marketing. While at Hoechst, he was responsible for marketing products in multiple therapeutic areas, including cardiology, allergy/respiratory, immunology, and neurology. Mr. Proehl holds a B.S. in Education from State University of New York at Cortland, an M.A. in Exercise Physiology from Wake Forest University, and an M.B.A. from Rockhurst University. Mr. Proehl currently serves as chairman of the board of one public company, Tenax Therapeutics, Inc. (NYSE: TENX). - Gerald T. Proehl于2014年12月成为董事、Dermata Therapeutics, Inc.总裁兼首席执行官，并于2021年4月成为Dermata Therapeutics, Inc.董事长。Proehl先生在制药行业拥有30多年的经验。从2002年1月到2014年1月，Proehl先生担任Santarus, Inc.的总裁兼首席执行官，在那里他以26亿美元的价格将Santarus，Inc.出售给了Salix Pharmaceuticals，Inc.。在加入Santarus, Inc.之前，Proehl先生曾在Hoechst Marion Roussel，Inc.工作了14年，担任过各种职务，包括全球营销副总裁。在Hoechst工作期间，他负责多个治疗领域的产品营销，包括心脏病、过敏/呼吸、免疫学和神经学。Proehl先生拥有纽约州立大学科特兰分校的教育学士学位、维克森林大学的运动生理学硕士学位和罗克赫斯特大学的工商管理硕士学位。Proehl先生目前在一家上市公司Tenax Therapeutics, Inc.（纽约证券交易所代码：TENX）担任Shlomo Kramer。由于Proehl先生在其他公司的领导经验以及他创立和经营专业制药公司的历史，他被选为高级管理人员和董事。
- Gerald T. Proehl,became a director and Dermata Therapeutics, Inc. President and Chief Executive Officer in December 2014 and became Dermata Therapeutics, Inc. Chairman in April 2021. From January 2002 until January 2014, Mr. Proehl was President and CEO of Santarus, Inc., where he led the sale of Santarus, Inc. to Salix Pharmaceuticals, Inc. for $2.6 billion. Prior to Santarus, Inc., Mr. Proehl worked for Hoechst Marion Roussel, Inc. for 14 years, where he served in various capacities, including VP of Global Marketing. While at Hoechst, he was responsible for marketing products in multiple therapeutic areas, including cardiology, allergy/respiratory, immunology, and neurology. Mr. Proehl holds a B.S. in Education from State University of New York at Cortland, an M.A. in Exercise Physiology from Wake Forest University, and an M.B.A. from Rockhurst University. Mr. Proehl currently serves as chairman of the board of one public company, Tenax Therapeutics, Inc. (NYSE: TENX).
- James Mitchum
-
James Mitchum在2013年11月被董事会为董事会成员以及审计委员会主席，该任命自募股完成后生效。从2009年到2012年7月，Mitchum先生担任EUSA Pharma USA, Inc.美国地区总裁，它负责监视业务的进行以及产品开发、FDA认证，并在2011年成功地推出了小儿肿瘤药物。从2005年到2008年，Mitchum先生担任Enturia, Inc.总裁以及首席执行官，该公司是一家私人药物设备公司，总部位于密苏里州堪萨斯市。从2004年到2005年，Mitchum先生担任Sanofi-Aventis Group Japan总裁以及首席执行官。Mitchum先生还在一些私有公司和组织担任董事。Mitchum先生从田纳西州约翰逊市的密立根学院（Milligan College）获得了商学和数学学士学位。
James Mitchum has served as a director since September 2015. Mr. Mitchum has served as the Chief Executive Officer of RegaloRx, a patient assistance provider since January 2019. From September 2014 to December 2018 he served as Chief Executive Officer of Heart to Heart International, a non-profit international humanitarian organization. From March 2009 to July 2012 Mr. Mitchum served as President of the Americas for EUSA Pharma, Inc., where he oversaw the streamlining of that business as well as the development, FDA approval and successful launch of a pediatric oncology drug in 2011. From 2005 to 2008 Mr. Mitchum served as President and Chief Executive Officer of Enturia, Inc., a privately owned drug-device company, based in Kansas City. From 2003 to 2005 Mr. Mitchum served as the President and Chief Executive Officer of Sanofi-Aventis Group Japan and was Chief Executive for Aventis Pharma UK from 2000 through 2002. He served in many senior financial roles from 1985 until 1999 with HMR and predecessor companies and was the Corporate Controller for HMR from 1997 until 2000. From 2014 until 2017 Mr. Mitchum served as a director and head of the audit committee for NephroGenex Inc., a development-stage company. Mr. Mitchum has also served as a director on numerous private company and organization boards. Mr. Mitchum earned an MBA in Business from the University of Tennessee in Knoxville, Tennessee and a Bachelor of Science degree in Business and Math from Milligan College in Johnson City, Tennessee. - James Mitchum在2013年11月被董事会为董事会成员以及审计委员会主席，该任命自募股完成后生效。从2009年到2012年7月，Mitchum先生担任EUSA Pharma USA, Inc.美国地区总裁，它负责监视业务的进行以及产品开发、FDA认证，并在2011年成功地推出了小儿肿瘤药物。从2005年到2008年，Mitchum先生担任Enturia, Inc.总裁以及首席执行官，该公司是一家私人药物设备公司，总部位于密苏里州堪萨斯市。从2004年到2005年，Mitchum先生担任Sanofi-Aventis Group Japan总裁以及首席执行官。Mitchum先生还在一些私有公司和组织担任董事。Mitchum先生从田纳西州约翰逊市的密立根学院（Milligan College）获得了商学和数学学士学位。
- James Mitchum has served as a director since September 2015. Mr. Mitchum has served as the Chief Executive Officer of RegaloRx, a patient assistance provider since January 2019. From September 2014 to December 2018 he served as Chief Executive Officer of Heart to Heart International, a non-profit international humanitarian organization. From March 2009 to July 2012 Mr. Mitchum served as President of the Americas for EUSA Pharma, Inc., where he oversaw the streamlining of that business as well as the development, FDA approval and successful launch of a pediatric oncology drug in 2011. From 2005 to 2008 Mr. Mitchum served as President and Chief Executive Officer of Enturia, Inc., a privately owned drug-device company, based in Kansas City. From 2003 to 2005 Mr. Mitchum served as the President and Chief Executive Officer of Sanofi-Aventis Group Japan and was Chief Executive for Aventis Pharma UK from 2000 through 2002. He served in many senior financial roles from 1985 until 1999 with HMR and predecessor companies and was the Corporate Controller for HMR from 1997 until 2000. From 2014 until 2017 Mr. Mitchum served as a director and head of the audit committee for NephroGenex Inc., a development-stage company. Mr. Mitchum has also served as a director on numerous private company and organization boards. Mr. Mitchum earned an MBA in Business from the University of Tennessee in Knoxville, Tennessee and a Bachelor of Science degree in Business and Math from Milligan College in Johnson City, Tennessee.
高管简历
中英对照 | 中文 | 英文- Stuart Rich
Stuart Rich自2021年1月起担任我们的首席医疗官，自2021年2月起担任董事。Rich博士从PHPM加入公司，他是该公司的联合创始人，并于2018年10月至2021年1月担任首席执行官兼董事。在加入PHPM之前，从2003年10月到2004年12月，Rich博士担任United Therapeutics的兼职首席医疗官。里奇博士目前担任西北大学范伯格医学院的医学教授，并担任英国慈善机构布鲁姆心血管研究所和美国慈善机构心血管医学与研究基金会的肺血管疾病计划主任。在西北大学之前，里奇医生是医学教授。从1980年7月到1996年7月，担任芝加哥伊利诺伊大学医学院心脏科科长，从1996年7月到2004年9月，担任拉什大学医学院拉什心脏研究所的医学教授。2004年9月至2015年7月，担任芝加哥大学普里茨克医学院心脏病学部分的医学教授。里奇博士在伊利诺伊大学获得生物学学士学位，在洛约拉大学斯特里奇医学院获得医学博士学位，并在华盛顿圣路易斯大学完成了医学住院医师学位，在芝加哥大学获得了心脏病学奖学金。
Stuart Rich has served as our Chief Medical Officer since January 2021 and a director since February 2021. Dr. Rich joined the Company from PHPM, where he was a co-founder and held the positions of Chief Executive Officer and Director from October 2018 until January 2021. Prior to PHPM, Dr. Rich served as the Chief Medical Officer part-time of United Therapeutics from October 2003 until December 2004. Dr. Rich currently serves as Professor of Medicine at Northwestern University Feinberg School of Medicine and as Director of the Pulmonary Vascular Disease Program at the Bluhm Cardiovascular Institute, a U.K. based charity, and of the Cardiovascular Medical and Research Foundation, a U.S. based charity. Prior to Northwestern University, Dr. Rich was the Professor of Medicine and Chief of the Section of Cardiology at the University of Illinois College of Medicine in Chicago from July 1980 until July 1996 was Professor of Medicine at the Rush Heart Institute of the Rush University School of Medicine from July 1996 until September 2004 and was Professor of Medicine at the Section of Cardiology of the University of Chicago Pritzker School of Medicine from September 2004 until July 2015. Dr. Rich received his B.S. in Biology at the University of Illinois and his M.D. at Loyola University Stritch School of Medicine, and he completed his residency in medicine at the Washington University of St. Louis and his fellowship in cardiology at the University of Chicago.- Stuart Rich自2021年1月起担任我们的首席医疗官，自2021年2月起担任董事。Rich博士从PHPM加入公司，他是该公司的联合创始人，并于2018年10月至2021年1月担任首席执行官兼董事。在加入PHPM之前，从2003年10月到2004年12月，Rich博士担任United Therapeutics的兼职首席医疗官。里奇博士目前担任西北大学范伯格医学院的医学教授，并担任英国慈善机构布鲁姆心血管研究所和美国慈善机构心血管医学与研究基金会的肺血管疾病计划主任。在西北大学之前，里奇医生是医学教授。从1980年7月到1996年7月，担任芝加哥伊利诺伊大学医学院心脏科科长，从1996年7月到2004年9月，担任拉什大学医学院拉什心脏研究所的医学教授。2004年9月至2015年7月，担任芝加哥大学普里茨克医学院心脏病学部分的医学教授。里奇博士在伊利诺伊大学获得生物学学士学位，在洛约拉大学斯特里奇医学院获得医学博士学位，并在华盛顿圣路易斯大学完成了医学住院医师学位，在芝加哥大学获得了心脏病学奖学金。
- Stuart Rich has served as our Chief Medical Officer since January 2021 and a director since February 2021. Dr. Rich joined the Company from PHPM, where he was a co-founder and held the positions of Chief Executive Officer and Director from October 2018 until January 2021. Prior to PHPM, Dr. Rich served as the Chief Medical Officer part-time of United Therapeutics from October 2003 until December 2004. Dr. Rich currently serves as Professor of Medicine at Northwestern University Feinberg School of Medicine and as Director of the Pulmonary Vascular Disease Program at the Bluhm Cardiovascular Institute, a U.K. based charity, and of the Cardiovascular Medical and Research Foundation, a U.S. based charity. Prior to Northwestern University, Dr. Rich was the Professor of Medicine and Chief of the Section of Cardiology at the University of Illinois College of Medicine in Chicago from July 1980 until July 1996 was Professor of Medicine at the Rush Heart Institute of the Rush University School of Medicine from July 1996 until September 2004 and was Professor of Medicine at the Section of Cardiology of the University of Chicago Pritzker School of Medicine from September 2004 until July 2015. Dr. Rich received his B.S. in Biology at the University of Illinois and his M.D. at Loyola University Stritch School of Medicine, and he completed his residency in medicine at the Washington University of St. Louis and his fellowship in cardiology at the University of Chicago.
- Anthony A. DiTonno
Anthony A. DiTonno在2003年8月至2011年12月间，担任公司的首席执行官，总裁和董事。在这之前，2003年初担任公司的首席运营官。Mr. DiTonno在Oxygen Biotherapeutics, Inc.（一个公开上市的生物制药公司）担任董事。2000年10月至2002年11月，Mr. DiTonno担任Enteric Medical Technologies, Inc.（一家医疗设备公司）的销售和营销执行副总裁。1997年至2000年，Mr. DiTonno担任LifeSleep Systems, Inc.（一家医疗设备公司）的首席执行官。1989年至1997年，Mr. DiTonno在Oclassen Pharmaceuticals, Inc.（一家制药公司）担任过许多职务，最近的职务是该公司的副总裁和总经理。Mr. DiTonno在St. Joseph's University获得工商管理学士学位，在Drexel University获得工商管理硕士学位。
Anthony A. DiTonno has served as a director since December 2011 and as Tenax Therapeutics, Inc.'s Chief Executive Officer since June 2018. From January 2013 until May 2018 Mr. DiTonno served as Chief Executive Officer of Avantis Medical Systems, Inc., a medical device company that develops and manufactures catheter-based endoscopic devices. From April 2003 until December 2011 Mr. DiTonno was President and Chief Executive Officer of Neurogesx Inc., a biopharmaceutical company based in the San Francisco Bay area "Neurogesx". During his time at Neurogesx, Mr. DiTonno also served on its board of directors. Mr. DiTonno has funded companies through a variety of financial arrangements including private and public financings, partnerships and debt. He has also been successful in gaining regulatory approvals in both the United States and European Union. Previously, he was Executive Vice President of Marketing and Sales at Enteric Medical Technologies Inc., which was acquired by Boston Scientific Company; President and Chief Executive Officer of Lifesleep Systems, Inc.; and Vice President and General Manager of Olcassen Pharmaceuticals, which was sold to Watson Laboratories. Early in his career, he held a variety of positions of increasing responsibility at Rorer Group, Inc. Rhone Poulenc Rorer and Wyeth Laboratories. Mr. DiTonno received an M.B.A. from Drexel University and a B.S. in Business Administration from St. Joseph's University.- Anthony A. DiTonno在2003年8月至2011年12月间，担任公司的首席执行官，总裁和董事。在这之前，2003年初担任公司的首席运营官。Mr. DiTonno在Oxygen Biotherapeutics, Inc.（一个公开上市的生物制药公司）担任董事。2000年10月至2002年11月，Mr. DiTonno担任Enteric Medical Technologies, Inc.（一家医疗设备公司）的销售和营销执行副总裁。1997年至2000年，Mr. DiTonno担任LifeSleep Systems, Inc.（一家医疗设备公司）的首席执行官。1989年至1997年，Mr. DiTonno在Oclassen Pharmaceuticals, Inc.（一家制药公司）担任过许多职务，最近的职务是该公司的副总裁和总经理。Mr. DiTonno在St. Joseph's University获得工商管理学士学位，在Drexel University获得工商管理硕士学位。
- Anthony A. DiTonno has served as a director since December 2011 and as Tenax Therapeutics, Inc.'s Chief Executive Officer since June 2018. From January 2013 until May 2018 Mr. DiTonno served as Chief Executive Officer of Avantis Medical Systems, Inc., a medical device company that develops and manufactures catheter-based endoscopic devices. From April 2003 until December 2011 Mr. DiTonno was President and Chief Executive Officer of Neurogesx Inc., a biopharmaceutical company based in the San Francisco Bay area "Neurogesx". During his time at Neurogesx, Mr. DiTonno also served on its board of directors. Mr. DiTonno has funded companies through a variety of financial arrangements including private and public financings, partnerships and debt. He has also been successful in gaining regulatory approvals in both the United States and European Union. Previously, he was Executive Vice President of Marketing and Sales at Enteric Medical Technologies Inc., which was acquired by Boston Scientific Company; President and Chief Executive Officer of Lifesleep Systems, Inc.; and Vice President and General Manager of Olcassen Pharmaceuticals, which was sold to Watson Laboratories. Early in his career, he held a variety of positions of increasing responsibility at Rorer Group, Inc. Rhone Poulenc Rorer and Wyeth Laboratories. Mr. DiTonno received an M.B.A. from Drexel University and a B.S. in Business Administration from St. Joseph's University.
- Michael B. Jebsen
2009年4月，Michael B. Jebsen加入Oxygen，担任我们的会计经理。2009年8月，他被选为财务总监，财务管理的执行副总裁。从2011年8月至2013年11月，Mr. Jebsen也担任我们临时首席执行官。在加入我们之前，从2003年7月至2005年12月，和从2008年4月至2009年4月，他担任Grant Thornton, LLP的核数师。此外，从2006年1月至2008年2月，他担任过各种职务，包括RTI International的首席道德官，高级的内部审计员和高级财务分析师，该机构是一个非营利性的研究和开发组织。Mr. Jebsen拥有East Carolina University会计理学硕士学位，也是在北卡罗莱纳州获准的一名注册会计师。
Michael B. Jebsen joined the Company as our Accounting Manager in April 2009 was elected Chief Financial Officer, Executive Vice President Finance and Administration in August 2009 and served as Interim Chief Executive Officer from April 2017 through May 2018. Mr. Jebsen also served as our Interim Chief Executive Officer from August 2011 until November 2013. Before joining us, he was an auditor with Grant Thornton, LLP from July 2003 through December 2005 and from April 2008 through April 2009. In addition, he held various positions, including Chief Ethics Officer, Senior Internal Auditor, and Senior Financial Analyst with RTI International, a non-profit research and development organization, from January 2006 to February 2008. Mr. Jebsen holds a Master of Science in Accounting from East Carolina University and is a Certified Public Accountant, licensed in North Carolina.- 2009年4月，Michael B. Jebsen加入Oxygen，担任我们的会计经理。2009年8月，他被选为财务总监，财务管理的执行副总裁。从2011年8月至2013年11月，Mr. Jebsen也担任我们临时首席执行官。在加入我们之前，从2003年7月至2005年12月，和从2008年4月至2009年4月，他担任Grant Thornton, LLP的核数师。此外，从2006年1月至2008年2月，他担任过各种职务，包括RTI International的首席道德官，高级的内部审计员和高级财务分析师，该机构是一个非营利性的研究和开发组织。Mr. Jebsen拥有East Carolina University会计理学硕士学位，也是在北卡罗莱纳州获准的一名注册会计师。
- Michael B. Jebsen joined the Company as our Accounting Manager in April 2009 was elected Chief Financial Officer, Executive Vice President Finance and Administration in August 2009 and served as Interim Chief Executive Officer from April 2017 through May 2018. Mr. Jebsen also served as our Interim Chief Executive Officer from August 2011 until November 2013. Before joining us, he was an auditor with Grant Thornton, LLP from July 2003 through December 2005 and from April 2008 through April 2009. In addition, he held various positions, including Chief Ethics Officer, Senior Internal Auditor, and Senior Financial Analyst with RTI International, a non-profit research and development organization, from January 2006 to February 2008. Mr. Jebsen holds a Master of Science in Accounting from East Carolina University and is a Certified Public Accountant, licensed in North Carolina.